People: aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Capital Market

16 Aug 2019
Change (% chg)

$0.20 (+7.14%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Mendlein, John 

Dr. John D. Mendlein, Ph.D., is Director of the Company. Dr. Mendlein served as our Chief Executive Officer from September 2011 to November 2017 and as Executive Chairman of the Board of Directors from July 2010 to December 2015. Dr. Mendlein is President, Corporate and Product Strategy and a director of Moderna Therapeutics, Inc., a biopharmaceutical company. Dr. Mendlein is Vice Chairman of the Board of Fate Therapeutics, Inc., a biopharmaceutical company, and also holds board positions with Editas Medicine, Inc. and Axcella Health, Inc., which are biopharmaceutical companies. Dr. Mendlein also serves on the Biotechnology Industry Organization ("BIO") emerging companies board. Dr. Mendlein previously served as the Chief Executive Officer of Adnexus Therapeutics, Inc., a biopharmaceutical company, from 2005 to 2008, which was purchased by Bristol-Myers Squibb Company in 2008. Dr. Mendlein also served on the board of directors of Monogram Biosciences, Inc., an HIV and oncology diagnostic company that was acquired by Laboratory Corporation of America Holdings in 2009. Before that, he served as Chairman and Chief Executive Officer of Affinium Pharmaceuticals, Ltd. (acquired by Debiopharm Group) from 2000 to 2005, and as a board member, General Counsel and Chief Knowledge Officer at Aurora Bioscience Corporation (acquired by Vertex Pharmaceuticals), a biotechnology company, from August 1996 to September 2001. Dr. Mendlein holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami. Dr. Mendlein is the co-author or co-inventor of over 210 publications and published patents, including a number of patents associated with our company.

Basic Compensation

Total Annual Compensation, USD 518,167
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,598,730
Fiscal Year Total, USD 3,116,900

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --